ChemoFx® PRO - A Post-Market Data Collection Study
ChemoFx® PRO - A Post-Market Data Collection Study Utilizing Physician Reported Outcomes
調査の概要
詳細な説明
The traditional treatment course for new cases of many cancers is cytoreductive surgery followed by chemotherapy. Unfortunately, despite high initial response rates to treatment, the majority of patients recur. The use of ineffective chemotherapy can result in unnecessary toxicity and costs, delay of more effective treatment, and the potential for the development of cross-resistance to additional drugs. The ability to individualize therapy by providing the treating physician with ex vivo response information on a panel of drugs should aid in the selection of effective therapy for individual patients, thus resulting in improved outcomes.
ChemoFx® is a drug response marker that quantifies an individual cancer patient's probable tumor response to various chemotherapeutic and biologic agents-providing both sensitivity and resistance information. In a retrospective study, it was demonstrated that patients treated with a regimen that the ChemoFx® test said the patients' cells would be sensitive to, corresponded to a 3 times longer progression free interval.
In the PT-206 ChemoFx PRO® study, patients will be followed through treatment, until the patient progresses or a significant change in chemotherapy occurs. This data will be collected and analyzed to identify potential patient cohorts for the development of hypotheses for future sub-study analysis. Also, tumor pathology slides and excess tumor cells (if available) will be used to characterize common polymorphisms in drug metabolizing enzymes as well as other molecular markers potentially associated with tumor response.
The PT-206 ChemoFx PRO® Study seeks to enroll an estimated 3,000 patients from 150 academic and community-based physicians in the U.S. The patients will be treated with drugs and/or drug combinations based on the medical judgment of the treating physician. This study is not randomized.
研究の種類
入学 (実際)
連絡先と場所
研究場所
-
-
Alabama
-
Birmingham、Alabama、アメリカ、35294
- University of Alabama at Birmingham
-
Mobile、Alabama、アメリカ、36688
- University Of South Alabama
-
-
California
-
San Francisco、California、アメリカ、94115
- University of California San Francisco
-
Sherman Oaks、California、アメリカ、91403
- Women's Cancer Center of Southern California
-
Torrance、California、アメリカ、91403
- GOA Torrance Memorial
-
-
Connecticut
-
Hartford、Connecticut、アメリカ、06106
- Hartford Hospital
-
New Haven、Connecticut、アメリカ、06111
- Yale University
-
-
Florida
-
Boca Raton、Florida、アメリカ、33487
- South Florida Center for Gynecologic Oncology
-
Clearwater、Florida、アメリカ、33756
- West Coast Gynecologic Oncology
-
Coconut Creek、Florida、アメリカ、33073
- Florida Center for Gynecologic Oncology
-
Delray Beach、Florida、アメリカ、33444
- Comprehensive Gynecologic Oncology
-
Fort Lauderdale、Florida、アメリカ、33308
- Caruso and Gates MDs PA
-
Fort Myers、Florida、アメリカ、33901
- Florida Gynecologic Oncology
-
Hollywood、Florida、アメリカ、33021
- Gynecologic Oncology Associates
-
Sarasota、Florida、アメリカ、34239
- Sarasota Memorial Hospital
-
South Miami、Florida、アメリカ、33143
- South Miami Gynecologic Oncology Group
-
West Palm Beach、Florida、アメリカ、33401
- Palm Beach Cancer Institute
-
-
Georgia
-
Riverdale、Georgia、アメリカ、30274
- Southeastern Gynecologic Oncology, LLC
-
Savannah、Georgia、アメリカ、31404
- Memorial Health University Medical Center
-
-
Hawaii
-
Honolulu、Hawaii、アメリカ、96813
- The Queens' Medical Center
-
-
Illinois
-
Chicago、Illinois、アメリカ、60612
- Rush University
-
Evanston、Illinois、アメリカ、60201
- Northshore Medical Group
-
-
Indiana
-
Indianapolis、Indiana、アメリカ、46202
- Indiana University
-
-
Louisiana
-
Covington、Louisiana、アメリカ、70433
- Women's Cancer Center
-
Shreveport、Louisiana、アメリカ、71101
- CHRISTUS Schumpert Health System
-
-
Maryland
-
Baltimore、Maryland、アメリカ、21215
- Sinai Hospital
-
Silver Springs、Maryland、アメリカ、20852
- Women's Health Specialists
-
-
Massachusetts
-
Worcester、Massachusetts、アメリカ、01605
- UMass Memorial Hospital
-
-
Michigan
-
Detroit、Michigan、アメリカ、48201
- Karmanos Cancer Institute
-
Detroit、Michigan、アメリカ、48202
- Henry Ford Health System
-
Grand Rapids、Michigan、アメリカ、49546
- Gynecologic Oncology of West Michigan
-
-
Mississippi
-
Jackson、Mississippi、アメリカ、39216
- Mississippi Oncology Associates
-
-
New Jersey
-
Morristown、New Jersey、アメリカ、07962
- Atlantic Health Systems
-
Neptune、New Jersey、アメリカ、07765
- Jersey Shore University Medical Center
-
Teaneck、New Jersey、アメリカ、07066
- Gara M Sommers MD
-
Voorhees、New Jersey、アメリカ、08043
- Cooper Health System
-
-
New York
-
Albany、New York、アメリカ、12208
- Women's Cancer Care Associates
-
Atlantic Beach、New York、アメリカ、11509
- St. John's Episcopal Hospital
-
Bronx、New York、アメリカ、10461
- Montefiore Medical Center
-
Buffalo、New York、アメリカ、14263
- Roswell Park Cancer Institute
-
Manhassett、New York、アメリカ、11030
- North Shore Lij Health System
-
New York、New York、アメリカ、10032
- Columbia University Medical Center
-
New York、New York、アメリカ、10038
- New York Downtown Hospital
-
-
North Carolina
-
Asheville、North Carolina、アメリカ、28806
- Hope: A Women's Cancer Center
-
Charlotte、North Carolina、アメリカ、28204
- Blumenthal Cancer Center
-
Charlotte、North Carolina、アメリカ、28233
- Presbyterian Gynecologic Oncology
-
Durham、North Carolina、アメリカ、27710
- Duke University Medical Center
-
Wilmington、North Carolina、アメリカ、28402
- North Hanover Regional Medical Center
-
-
Ohio
-
Cincinnati、Ohio、アメリカ、45267
- University of Cincinnati
-
Columbus、Ohio、アメリカ、43026
- OSU Gynecologic Oncology
-
-
Oklahoma
-
Oklahoma City、Oklahoma、アメリカ、73112
- Oklahoma Gynecologic Oncology Group
-
-
Oregon
-
Portland、Oregon、アメリカ、97239
- Oregon Health & Science University
-
-
Pennsylvania
-
Pittsburgh、Pennsylvania、アメリカ、15224
- The Western Pennsylvania Hospital
-
Pittsburgh、Pennsylvania、アメリカ、15224
- Allegheny-Singer Research Institute
-
-
Rhode Island
-
Providence、Rhode Island、アメリカ、02905
- Women & Infants Hospital of Rhode Island
-
-
South Carolina
-
Charleston、South Carolina、アメリカ、29403
- Medical University of South Carolina Hospital
-
-
South Dakota
-
Sioux Falls、South Dakota、アメリカ、57105
- Sandford USD Health System
-
-
Tennessee
-
Chattanooga、Tennessee、アメリカ、37403
- Chattanooga's Program in Women's Oncology
-
Chattanooga、Tennessee、アメリカ、37403
- Chattanooga Gynecologic Oncology
-
Knoxville、Tennessee、アメリカ、37922
- Thomas W. McDonald MD
-
-
Texas
-
Dallas、Texas、アメリカ、75251
- North Texas Gynecologic Oncology
-
Ft. Sam Houston、Texas、アメリカ、78234
- Brooke Army Medical Center
-
San Antonio、Texas、アメリカ、78258
- South Texas Gynecologic Oncology
-
-
Virginia
-
Annandale、Virginia、アメリカ、22003
- North Virigina Pelvic Surgery Associates
-
Roanoke、Virginia、アメリカ、24016
- Carilion Clinic Gynecologic Oncology
-
-
West Virginia
-
Morgantown、West Virginia、アメリカ、26505
- Mohammed Ashraf MD
-
-
Wisconsin
-
West Allis、Wisconsin、アメリカ、53227
- Aurora West Allis Medical Center
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
サンプリング方法
調査対象母集団
Approximately 3,000 patients from 150 academic and community based physicians in the United States.
Patients have a confirmed solid tumor malignancy and their tissue specimen has been submitted to Precision Therapeutics, Inc. as part of the patient's medical care
説明
Inclusion Criteria:
- Patient has been diagnosed with a solid tumor malignancy and their physician has received a final report for ChemoFx® after August 1, 2006
- Chemotherapy must be clinically indicated for treatment of the patient's qualifying disease
- Patient must be at least 18 years of age
- Patient must have signed an IRB approved informed consent form for the data collection study prior to entry of data into the enrollment form in the database.
Exclusion Criteria:
- Patient pathology shows benign pathology for sample submitted
- Patient is not indicated to receive chemotherapy for their disease
研究計画
研究はどのように設計されていますか?
デザインの詳細
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
時間枠 |
---|---|
To collect physician reported outcomes after the first chemotherapy utilized following the receipt of a final report from ChemoFx® in solid tumor malignancies for the generation of hypotheses for further sub-study.
時間枠:24-36 Months depending on Disease Status
|
24-36 Months depending on Disease Status
|
二次結果の測定
結果測定 |
時間枠 |
---|---|
Identify possible enhancements of the predictive and prognostic capabilities of the assay through the inclusion of molecular markers.
時間枠:24-36 Months depending on Disease Status
|
24-36 Months depending on Disease Status
|
協力者と研究者
スポンサー
出版物と役立つリンク
一般刊行物
- Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E, Feuer EJ, Thun MJ; American Cancer Society. Cancer statistics, 2004. CA Cancer J Clin. 2004 Jan-Feb;54(1):8-29. doi: 10.3322/canjclin.54.1.8.
- Ness RB, Wisniewski SR, Eng H, Christopherson W. Cell viability assay for drug testing in ovarian cancer: in vitro kill versus clinical response. Anticancer Res. 2002 Mar-Apr;22(2B):1145-9.
- O'Meara AT, Sevin BU. Predictive value of the ATP chemosensitivity assay in epithelial ovarian cancer. Gynecol Oncol. 2001 Nov;83(2):334-42. doi: 10.1006/gyno.2001.6395.
- McLeod HL, King CR, Marsh S. Application of pharmacogenomics in the individualization of chemotherapy for gastrointestinal malignancies. Clin Colorectal Cancer. 2004 Jun;4 Suppl 1:S43-7. doi: 10.3816/ccc.2004.s.007.
研究記録日
主要日程の研究
研究開始
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (見積もり)
学習記録の更新
投稿された最後の更新 (見積もり)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。
子宮頸癌の臨床試験
-
Jonsson Comprehensive Cancer CenterNational Cancer Institute (NCI); Highlight Therapeutics積極的、募集していない平滑筋肉腫 | 悪性末梢神経鞘腫瘍 | 滑膜肉腫 | 未分化多形肉腫 | 骨の未分化高悪性度多形肉腫 | 粘液線維肉腫 | II期の体幹および四肢の軟部肉腫 AJCC v8 | III期の体幹および四肢の軟部肉腫 AJCC v8 | IIIA 期の体幹および四肢の軟部肉腫 AJCC v8 | IIIB 期の体幹および四肢の軟部肉腫 AJCC v8 | 切除可能な軟部肉腫 | 多形性横紋筋肉腫 | 切除可能な脱分化型脂肪肉腫 | 切除可能な未分化多形肉腫 | 軟部組織線維肉腫 | 紡錘細胞肉腫 | ステージ I 後腹膜肉腫 AJCC (American Joint Committee on Cancer) v8 | 体幹および四肢の I 期軟部肉腫 AJCC v8 | ステージ... およびその他の条件アメリカ